(MENAFN- ProactiveInvestors - Australia) Suda Limited (ASX: SUD) has been granted a trading halt today by the ASX and placed in pre-open pending details of a material acquisition.
Suda has not yet released any further details, with the company currently focused on commercialising low-risk pharmaceutical projects.
The company's lead product is ArTiMistâ„¢, a sub-lingual artemether based malaria treatment which has been developed specifically for children with severe malaria. ArTiMistâ„¢ is currently in Phase III clinical trials in Africa.
The halt will last until the earlier of an announcement being made to the market, or the opening of trade on Friday 21st December 2012.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.